Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

3 Brilliant Biotech Stocks to Buy for Your Portfolio

The biotech industry is flourishing on the backs of positive clinical trials and new developments. Thus, it could be beneficial to add fundamentally robust biotech stocks BioMarin Pharmaceutical (BMRN), Equillium (EQ), and Organogenesis Holdings (ORGO) to your portfolios. Read more….

StockNews.com

About the new drug pricing negotiations

The first eligible drugs treat diabetes, blood clots, blood cancers, arthritis and heart disease

Salon

5 things consumers need to know about Medicare’s new drug-pricing negotiations, how they’ll affect you

This could help people whose Medicare drug plans require big copayments. But the main relief will come from part of the Inflation Reduction Act that caps drug spending by Medicare recipients at $2,000 a year starting in 2025.

Chicago Sun-Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Medicare Lists First 10 Drugs for Talks On Lowering Your Costs

New prices for Medicare Part D drugs on list expected in 2026.

Kiplinger

3 Best Biotech Stocks for Growth in 2023

The biotech industry is well-positioned for solid growth due to the growing demand for high-quality treatments for chronic diseases and an aging population. Therefore, it could be wise to invest in fundamentally strong biotech stocks Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), and Gilead Sciences (GILD), given their solid growth prospects. Read…

StockNews.com

Staffordshire-based Instem bought by private equity group for £203m

Instem is second UK life sciences company this week to be snapped up by a foreign buyer

The Guardian - UK

Biden touts Medicare negotiating drug prices: ‘Today is the start of a new deal for patients’

Announcement comes as Medicare names the drugs it will begin negotiations for prices

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

3M agrees to multi-billion dollar settlement in earplug lawsuits from U.S. service members

Chemical and consumer product manufacturer 3M has agreed to pay $6 billion to settle numerous lawsuits from U.S. service members who say they experienced hearing loss or other serious injuries from using earplugs made by the company

The Independent UK

3 Best Biotech Stocks for Health and Wealth

With medical innovations and technological breakthroughs rapidly transforming the healthcare landscape, biotech stocks have garnered unprecedented attention in the investment community. Thus, fundamentally robust stocks like Incyte Corp. (INCY), Vertex Pharmaceuticals (VRTX), and Amgen (AMGN) could contribute to the health and wealth of your portfolios. Read more….

StockNews.com

What Biden’s announcement of Medicare negotiating drug prices means

Democrats have long wanted to allow Medicare to negotiate drug prices, which it hopes will lead to lower prescription costs

The Independent UK

3M agrees to pay $6 billion to settle earplug lawsuits from U.S. service members

The Independent UK

Here are the first 10 drugs that Medicare will target for price cuts

The government will negotiate new prices for the commonly prescribed drugs, but the cuts won't take effect until 2026. In the meantime, drugmakers are fighting the negotiations with lawsuits.

WEKU

Texas can now apply to import lower-priced Canadian medications

Texas joins a handful of states turn to the north for cheaper drugs. But feds have been slow to approve requests, three years after giving initial OK.

The Texas Tribune

CVS Launches Cordavis to Target Biosimilars Market

New CVS unit aims to cut your prescription costs by offering alternatives to branded drugs.

Kiplinger

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Is Johnson & Johnson (JNJ) a Buy Before September Begins?

Pharma giant Johnson & Johnson (JNJ) has posted robust second-quarter results and raised its full-year outlook. Should investors look into the stock before September begins? Let’s look at its financial metrics to gauge its prospects….

The Guardian - US

Vivek Ramaswamy says he wants Elon Musk to be his presidential adviser

Republican candidate and biotech entrepreneur names Twitter CEO when asked about potential advisers should he win election

StockNews.com

3 Biotech Stocks to Buy This Month and Beyond

Owing to the critical medical needs, the lookout for new technologies to deal with future advancements is at its peak. Breakthrough innovations, revolutionary treatments, and a booming industry align to make biotech stocks a potential goldmine for savvy investors. Therefore, it could be wise to invest in quality biotech stocks…

StockNews.com

3 Medical Stocks Dominating the Industry

Thanks to the non-cyclical nature and the increasing demand for healthcare services, the healthcare industry should continue to brave most market challenges. Hence, it could be an opportune time to explore dominating medical stocks: Elevance Health (ELV), Centene Corp. (CNC), and Molina Healthcare (MOH), which might garner substantial returns for…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Pharma Stocks With Promising Pipelines

The pharma industry is anticipated to stay buoyed in the years to come with consistent medical breakthroughs and rising need to serve an aging population. Therefore, pharma stocks Johnson & Johnson (JNJ), Novartis AG (NVS), and Dr. Reddy's Laboratories (RDY), which possess promising pipelines, could be wise portfolio additions now.…

StockNews.com

Pfizer Inc. (PFE) vs. Teva Pharmaceutical Industries (TEVA): Which Stock is the Better Growth AND Value Buy?

The pharmaceutical sector appears to be in a favorable position for sustained long-term expansion. While leading pharma stocks Pfizer (PFE) and Teva Pharmaceuticals (TEVA) should benefit from the industry tailwinds, let us analyze which is the better buy for Growth and Value.

The Guardian - UK

FTSE 100 bosses ‘given average pay rise of £500,000 in 2022’

CEOs received average increase of 16% while pay of many working for them failed to keep up with inflation

Newsroom.co.nz

Buy-now-pay-later closure hits unfunded medicines

Businesses relying on the popular but contentious payments model are finding their operations increasingly difficult to stack up, reports Andrew Bevin.

StockNews.com

Catalyst Pharmaceuticals (CPRX): Is Now the Time to Buy This Pharma Stock?

Catalyst Pharmaceuticals (CPRX) reported robust second-quarter results, with its topline reaching an all-time high. Does that mean it's time to buy the pharma stock now? Let’s look at its financial metrics to gauge its prospects….

Salon

Big Pharma’s playbook for expensive meds

Here are just a few of the many examples of drug pricing practices that have driven consumers to demand change

The Guardian - US

What is the abortion case in front of the US supreme court right now?

On Tuesday the justices heard oral arguments on a rightwing effort to roll back access to a key abortion pill

1 … 46 47 48 49

People

Jennifer Walker Elrod

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Department of Justice

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.